ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

Autor: Víctor A. Arrieta, Bin Zhang, Daniel J. Brat, Xiaoyang Ling, Daniel Zhang, Jinzhou Yuan, David Cieremans, Timothy F. Cloughesy, Lee Cooper, Peter Canoll, Robert M. Prins, Matthew McCord, Roger Stupp, Christina Amidei, Adam M. Sonabend, Gerson Rothschild, Catalina Lee-Chang, Li Chen, Cynthia Kassab, Pavan S. Upadhyayula, Jonathan T. Yamaguchi, Wenting Zhao, Dinesh Jaishankar, Kirsten Bell Burdett, Brice Laffleur, Amy B. Heimberger, Seong Jae Kang, Hui Zhang, Uttiya Basu, Andrew X. Chen, J. Robert Kane, Craig Horbinski, Peter A. Sims, Crismita Dmello, Jared K. Burks, Joseph Shilati, Jeffrey N. Bruce, Fabio M. Iwamoto, Raul Rabadan, Andrew Gould, Rimas V. Lukas, Junfei Zhao

Publikováno v: Nature Cancer
Nature Cancer, Nature Research 2021, 2 (12), pp.1372-+. ⟨10.1038/s43018-021-00260-2⟩
Nat Cancer
Nature Cancer, 2021, 2 (12), pp.1372-+. ⟨10.1038/s43018-021-00260-2⟩

International audience; In two cohorts of patients with glioblastoma who received anti-PD-1, Sonabend and colleagues show that ERK1/2 phosphorylation, detected by immunohistochemistry, provides a biomarker for MAPK/ERK pathway activity and better sur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bb3e07ae1ffbbff3b9efdc0412296b0
https://pubmed.ncbi.nlm.nih.gov/35149861

BIOM-31. ERK1/2 PHOSPHORYLATION PREDICTS SURVIVAL FOLLOWING ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA

Autor: Raul Rabadan, Jeffrey N. Bruce, Peter A. Sims, Daniel J. Brat, Matthew R McCord, Pavan S. Upadhyayula, Andrew Gould, Hui Zhang, Gerson Rothschild, Xiaoyang Ling, Kirsten Bell Burdett, Fabio M. Iwamoto, Lee Cooper, Joseph Shilati, Rimas V. Lukas, Junfei Zhao, Cynthia Kassab, Uttiya Basu, Brice Laffleur, Wenting Zhao, Dinesh Jaishankar, Li Chen, Daniel Zhang, Peter Canoll, Robert M. Prins, Amy B. Heimberger, J. Robert Kane, Timothy F. Cloughesy, Catalina Chang, Crismita Dmello, Jared K. Burks, Craig Horbinski, Jinzhou Yuan, David Cieremans, Jonathan T. Yamaguchi, Andrew X. Chen, Roger Stupp, Christina Amidei, Víctor A. Arrieta, Bin Zhang, Adam M. Sonabend, Seong Jae Kang

Publikováno v: Neuro-Oncology. 23:vi17-vi17

PD-1 checkpoint inhibition has led to remarkable clinical responses in several cancer types. Whereas PD-1 blockade has not shown an overall survival (OS) benefit for glioblastoma (GBM) patients, a subset of them exhibit long-term responses to this im

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a3dc2336f73232af4ed232db838d44d0
https://doi.org/10.1093/neuonc/noab196.062